Imagyn sells surgical needle line to Surgical Supply:
This article was originally published in Clinica
Imagyn Medical Technologies is to sell its surgical needle product line to Surgical Supply for $7.65 million. Newport Beach, California-based Imagyn will use the proceeds from the sale to reduce debt. The company is disposing of certain non-core assets and hopes to reach agreement concerning further sales during this quarter. Separately, Imagyn plans to begin commercial shipment of International Isotopes' brachytherapy seed, IsoStar, for which it has exclusive distribution rights.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.